OS Therapies has secured full alignment with the UK MHRA and European EMA on its Conditional Marketing Authorisation Application (CMAA) for its gene-edited cancer immunotherapy OST-HER2 targeting metastatic osteosarcoma. The regulators agreed on using historical control data and the Phase 3 trial design, which OS Therapies plans to start in Q4 2026. The company aims to submit the CMAA soon and is also pursuing FDA approval under the Accelerated Approval Program, potentially gaining early market access and a Priority Review Voucher. This regulatory progress marks a significant step toward commercializing OST-HER2, which has shown promising Phase 2 results in preventing recurrence of osteosarcoma.
OS Therapies' regulatory progress is noted here alongside Pluang's market data for health stocks. For readers following health stocks, here is Pluang's market snapshot as of Sep 15, 2026 18:13 WIB: out of 91 priced US health stocks, 31 rose and 54 fell. Notable movers include ASND at USD 258.00 (-2.61%), INO at USD 1.21 (+2.54%), and DNA at USD 6.86 (-2.14%).
Mid-America Apartment Communities, Inc. (MAA), a major apartment REIT focused on the U.S. Sunbelt region, faces mixed analyst opinions as it prepares for the BofA Securities 2026 Global Real Estate Conference on September 16. Analysts have recently a...
UBS lowered its price target for Comcast from $32 to $27, citing expected higher broadband subscriber losses, weaker theme-park results, and lower revenue and EBITDA in the near term. Comcast is also undergoing a major restructuring to spin off NBCUn...
Hooker Furniture Corporation reported Q3 2026 revenue of $63.3 million and operating income of $1.3 million, beating consensus on profitability despite slightly missing revenue estimates. The company’s gross margin expanded significantly to 31.8%, la...
Backblaze received a Buy rating with a $16 price target due to strong growth in its B2 Cloud Storage segment, which saw 34% revenue growth in Q2. Core growth excluding price increases was about 26%, and new large AI contracts such as CoreWeave improv...
Robinhood and Webull shares fell about 4% as the U.S. Senate prepared to vote on the CLARITY Act, a bill aimed at establishing clearer regulations for cryptocurrency markets. The vote's outcome is uncertain, causing investor anxiety since both broker...
